Date:7/29/2009

LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and other accrued liabilities $2,049,936 $2,150,980 Accrued clinical expense 1,321,786 1,865,773 Accrued compensation 415,007 537,215 Accrued restructuring charges 59,993 191,170 Current portion of deferred rent 23,308 1,409,513 Current portion of deferred revenue 2,083 27,083 ----- ------ Total current liabilities 3,872,113 6,181,734 Non-current portion of deferred rent 87,755 110,919 Commitments Stockholders' equity: Convertible preferred stock 56,163,436 - Common stock 3,442 3,441 Additional paid-in capital 297,092,539 322,671,604 Accumulated other comprehensive income 127 7,841 Accumulated deficit (347,433,609) (316,191,710) ------------ ------------ Total stockholders' equity 5,825,935 6,491,176 --------- --------- Total liabilities and stockholders' equity $9,785,803 $12,783,829 ========== =========== Note 1: The condensed consolidated balance sheet as of December 31, 2008 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2008.

                               SUNESIS PHARMACEUTICALS, INC.
                   CONDENSED CO
'/>"/>
SOURCE  Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 
Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences